Royal Holloway University of London-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2022

  1. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  2. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Researcher's Perceptions on Publishing "negative" Results and Open Access

    Nucleic Acid Therapeutics, Vol. 31, Núm. 3, pp. 185-189

2011

  1. Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice

    Molecular Therapy, Vol. 19, Núm. 2, pp. 345-354

  2. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study

    The Lancet, Vol. 378, Núm. 9791, pp. 595-605

2010

  1. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials

    Neuromuscular Disorders, Vol. 20, Núm. 2, pp. 102-110

2009

  1. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

    The Lancet Neurology, Vol. 8, Núm. 10, pp. 918-928

2007

  1. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle

    Human Gene Therapy, Vol. 18, Núm. 9, pp. 798-810

1997

  1. Antioxidant activity of phytoestrogenic isoflavones

    Free Radical Research, Vol. 26, Núm. 1, pp. 63-70